• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BRAF inhibitors in metastatic non-small cell lung cancer.

作者信息

Anguera Geòrgia, Majem Margarita

机构信息

Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

出版信息

J Thorac Dis. 2018 Feb;10(2):589-592. doi: 10.21037/jtd.2018.01.129.

DOI:10.21037/jtd.2018.01.129
PMID:29607117
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5864601/
Abstract
摘要

相似文献

1
BRAF inhibitors in metastatic non-small cell lung cancer.BRAF抑制剂在转移性非小细胞肺癌中的应用
J Thorac Dis. 2018 Feb;10(2):589-592. doi: 10.21037/jtd.2018.01.129.
2
Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.真实世界中 BRAF V600 突变型转移性非小细胞肺癌患者的治疗模式和生存情况。
Lung Cancer. 2019 Feb;128:74-90. doi: 10.1016/j.lungcan.2018.12.003. Epub 2018 Dec 6.
3
Encorafenib plus binimetinib in patients with -mutant non-small cell lung cancer: phase II PHAROS study design.恩考芬尼联合比美替尼治疗 - 突变型非小细胞肺癌患者：PHAROS 期临床试验设计。
Future Oncol. 2022 Mar;18(7):781-791. doi: 10.2217/fon-2021-1250. Epub 2021 Dec 17.
4
Adverse Event Management in Patients with V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib.V600E 突变型非小细胞肺癌患者接受达拉非尼联合曲美替尼治疗的不良事件管理。
Oncologist. 2019 Jul;24(7):963-972. doi: 10.1634/theoncologist.2018-0296. Epub 2018 Dec 31.
5
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring Mutations.FDA 批准概要：达拉非尼联合曲美替尼治疗携带突变的转移性非小细胞肺癌。
Oncologist. 2018 Jun;23(6):740-745. doi: 10.1634/theoncologist.2017-0642. Epub 2018 Feb 7.
6
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.针对 BRAF 突变型非小细胞肺癌：现状与未来方向。
Lung Cancer. 2022 Jul;169:102-114. doi: 10.1016/j.lungcan.2022.05.014. Epub 2022 May 26.
7
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
[Expert consensus on the diagnosis and treatment in advanced non-small cell lung cancer with BRAF mutation in China].中国BRAF突变型晚期非小细胞肺癌诊疗专家共识
Zhonghua Zhong Liu Za Zhi. 2023 Apr 23;45(4):279-290. doi: 10.3760/cma.j.cn112152-20230117-00030.
9
Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.携带BRAF突变的肺癌患者的临床特征与预后
Lung Cancer. 2016 Jan;91:23-8. doi: 10.1016/j.lungcan.2015.11.006. Epub 2015 Nov 15.
10
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.局部晚期和转移性非小细胞肺癌的系统治疗：综述。
JAMA. 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058.

引用本文的文献

1
BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications.实体瘤中的BRAF靶向治疗：分子层面与临床应用
Int J Mol Sci. 2025 Apr 16;26(8):3757. doi: 10.3390/ijms26083757.
2
Biomarker testing in lung cancer: from bench to bedside.肺癌中的生物标志物检测：从实验室到临床
Oncol Rev. 2025 Jan 6;18:1445826. doi: 10.3389/or.2024.1445826. eCollection 2024.
3
Navigating the complexity of BRAF mutations in non-small cell lung cancer: current insights and future prospects.应对非小细胞肺癌中BRAF突变的复杂性：当前见解与未来展望
Multidiscip Respir Med. 2024 Nov 15;19(1):992. doi: 10.5826/mrm.2024.992.
4
Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids.双重靶向 MAPK 和 PI3K 通路可解锁 BRAF 突变型甲状腺癌类器官的再分化。
Oncogene. 2024 Jan;43(3):155-170. doi: 10.1038/s41388-023-02889-y. Epub 2023 Nov 20.
5
Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.利用 MassARRAY 系统上的 UltraSEEK 肺癌 panel 检测和监测转移性非小细胞肺癌患者循环肿瘤 DNA 中的肿瘤衍生突变。
Int J Mol Sci. 2023 Aug 29;24(17):13390. doi: 10.3390/ijms241713390.
6
KRAS and NRAS Translation Is Increased upon MEK Inhibitors-Induced Processing Bodies Dissolution.在MEK抑制剂诱导加工小体溶解后，KRAS和NRAS的翻译增加。
Cancers (Basel). 2023 Jun 6;15(12):3078. doi: 10.3390/cancers15123078.
7
A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer.肺癌新型治疗靶点及免疫治疗的研究进展述评。
Med Oncol. 2023 Apr 18;40(5):152. doi: 10.1007/s12032-023-02005-w.
8
Emerging genetic biomarkers in lung adenocarcinoma.肺腺癌中新兴的基因生物标志物
SAGE Open Med. 2022 Oct 18;10:20503121221132352. doi: 10.1177/20503121221132352. eCollection 2022.
9
Large Pleural Effusion Secondary to Primary Signet-Ring Cell Adenocarcinoma of the Lung.原发性肺印戒细胞腺癌继发大量胸腔积液
Cureus. 2021 Nov 23;13(11):e19846. doi: 10.7759/cureus.19846. eCollection 2021 Nov.
10
Inhibition of RAF dimers: it takes two to tango.抑制 RAF 二聚体：孤掌难鸣。
Biochem Soc Trans. 2021 Feb 26;49(1):237-251. doi: 10.1042/BST20200485.

本文引用的文献

1
Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.高加索非小细胞肺癌患者的致癌驱动基因突变、治疗及表皮生长因子受体酪氨酸激酶抑制剂耐药性：临床实践中的生存情况
Oncotarget. 2017 Sep 13;8(44):77897-77914. doi: 10.18632/oncotarget.20857. eCollection 2017 Sep 29.
2
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.达拉非尼联合曲美替尼治疗既往未经治疗的 BRAF 突变型转移性非小细胞肺癌的开放标签、2 期临床试验。
Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.
3
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.IV期非小细胞肺癌的全身治疗：美国临床肿瘤学会临床实践指南更新摘要
J Oncol Pract. 2017 Dec;13(12):832-837. doi: 10.1200/JOP.2017.026716. Epub 2017 Aug 29.
4
Targeting -Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.靶向 - 突变型非小细胞肺癌：从分子剖析到合理设计的治疗
Oncologist. 2017 Jul;22(7):786-796. doi: 10.1634/theoncologist.2016-0458. Epub 2017 May 9.
5
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.达拉非尼联合曲美替尼治疗既往接受过治疗的BRAF（V600E）突变转移性非小细胞肺癌患者：一项开放标签、多中心2期试验。
Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6.
6
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.达拉非尼用于BRAF（V600E）阳性晚期非小细胞肺癌患者：一项单臂、多中心、开放标签的2期试验。
Lancet Oncol. 2016 May;17(5):642-50. doi: 10.1016/S1470-2045(16)00077-2. Epub 2016 Apr 11.
7
Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.携带BRAF突变的肺癌患者的临床特征与预后
Lung Cancer. 2016 Jan;91:23-8. doi: 10.1016/j.lungcan.2015.11.006. Epub 2015 Nov 15.
8
Lung Cancer Statistics.肺癌统计数据。
Adv Exp Med Biol. 2016;893:1-19. doi: 10.1007/978-3-319-24223-1_1.
9
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.维莫非尼用于治疗伴有BRAF V600突变的多种非黑色素瘤癌症。
N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.
10
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.克唑替尼对比化疗用于治疗 ALK 阳性肺癌。
N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440.